N/A
N=17
Dorsal Wrist Ganglia; Aspiration Alone vs Aspiration and Injection of Platelet Rich Plasma
Ganglion of Wrist
Bottom Line
View on ClinicalTrials.gov: NCT03408808 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Number of Participants With a Recurrence of Ganglia — 8; 5 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Platelet rich plasma (Procedure); Aspiration alone (Procedure)
- Age
- Pediatric, Adult, Older Adult · 16+ yrs
- Sex
- All
- Sponsor
- University of Aberdeen
- Primary completion
- Feb 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With a Recurrence of Ganglia |
3; 7 | — |
| PRIMARY Number of Participants With a Recurrence of Ganglia |
3; 7 | — |
| SECONDARY PEM Score |
35; 40.6 | — |
| SECONDARY PEM Score |
35; 40.6 | — |
Summary
Study to examine the efficacy of Platelet Rich Plasma (PRP) to reduce recurrence in dorsal wrist ganglia (DWG). We will compare aspiration alone and aspiration with injection of PRP.
We plan to recruit a maximum of 200 patients. We will assess the efficacy by contacting the patients by email or telephone at 6 weeks and 12 months. They will be asked to complete a questionnaire and a Patient Evaluated Measure score (PEMS). Adverse events will be screened for/ managed by a telephone call +/- review as necessary between 7 and 14 days.
Eligibility Criteria
Inclusion Criteria
- Solitary dorsal wrist ganglion.
Exclusion Criteria
- Underlying wrist or ipsilateral arm pathology.
- Unable to consent to treatment.
- Unable or unwilling to attend follow up visits.
Data sourced from ClinicalTrials.gov (NCT03408808). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.